Page 232 - 82_ex2

Juan Tamargo
8. Carvajal R, Wadden TA, Tsai AG, Peck K, Moran
CH. Managing obesity in primary care practice: a
narrative review. Ann New York Acad Sci 2013;
1281: 191-206.
9. Garvey WT. New tools for weight loss therapy enable
a more robust medical model for obesity treatment:
rationale for a complications-centric approach. Endocr
Pract 2013; 19: 864-74.
10. Kahan S, Ferguson C, David S, Divine L. Obesity
drug outcome measures: Results of a multi-
stakeholder critical dialoque. Current Obesity Reports
2013; 2: 128-33.
11. Korner J, Aronne LJ. Pharmacological approaches to
weight reduction: therapeutic targets. J Clin
Endocrinol Metab 2004; 89: 2616–21.
12. Yanovski SZ, Bain RP, Williamson DF. Report of a
National Institutes of Health-centers for disease
control and prevention workshop on the feasibility of
conducting a randomized clinical trial to estimate the
long-term health effects of intentional weight loss in
obese persons. Am J Clin Nutrition 1999; 69: 366-72.
13. Clinical Guidelines on the Identification, Evaluation, professionals advising obese patients to lose weight?
and Treatment of Overweight and Obesity in Adults.
The Evidence Report, NIH Publication No. 98-4083,
NIH Publication, Bethesda, Md, USA 2000.
Disponible en
http://www.nhlbi.nih.gov/files/docs/guidelines/prctgd
_c.pdf
14. Foster GD, Wadden TA, Vogt RA, Brewer G. What is
a reasonable weight loss? Patients' expectations and
evaluations of obesity treatment outcomes. J Consult
Clin Phsych 1997; 65: 79-85.
15. Wadden TA, Womble LG, Sarwer DB, Berkowitz RI,
Clark VL, Foster GD. Great expectations: I'm losing
25 % of my weight no matter what you say. J Consult
Clin Phsych 2003; 71: 1084-9.
16. Wadden TA, Berkowitz RI, Womble LF, et al.
Randomized trial of lifestyle modification and
pharmacotherapy for obesity. N Engl J Med 2005;
353: 2111-20.
17. Middleton KM, Patidar SM, Perri MG. Impact of
extended care on the long-term maintenance of weight
loss: a systematic review and meta-analysis. Obes Rev
2012; 13: 509-17.
18. Colman E, Golden J, Roberts M, Egan A, Weaver J,
Rosebraugh C. The FDA's assessment of two drugs
for chronic weight management. N Engl J Med 2012;
367: 1577-9.
19. Colman E. Food and Drug Administration's Obesity
Drug Guidance Document: a short history. Circulation
2012; 125: 2156-64.
20. Rissanen A, Lean M, Rossner S, Segal KR, Sjostrom
L. Predictive value of early weight loss in obesity
management with orlistat: an evidence-based
assessment of prescribing guidelines. Int J Obes Relat
Metab Disord 2003; 27: 103-9.
222
21. Golden J. US Food and Drug Administration
Endocrinologic and Metabolic Drugs Advisory
Committee Clinical Briefing Document May 10,
Arena Pharmaceuticals, Inc; New Drug Application
022529: Lorcaserin hydrochloride tablets 10mg. 2012.
Disponible en
http://www.fda.gov/downloads/AdvisoryCommittees/
CommitteesMeetingMaterials/Drugs/Endocrinologica
ndMetabolicDrugsAdvisoryCommittee/UCM303198.
pdf. [Accessed 10/5/2013].
22. Blackburn G. Effect of degree of weight loss on health
benefits. Obs Res 1995; 3 (Suppl. 2): 211s-6.
23. Kanders BS, Blackburn GL, Lavin P, Norton D.
Weight loss outcome and health benefits associated
with the Optifast program in the treatment of obesity.
Int J Obesity 1989; 13 (Suppl.): 131-4.
24. Follick MJ, Abrams DB, Smith TW. Contrasting
short- and long-term effects of weight loss on
lipoprotein levels. Arch Intern Med 1984; 144: 1571-
4.
25. Galuska DA, Will JC, Serdula MK. Are health care
JAMA-J Am Med Assoc 1999; 282: 1576-8.
26. Connolly HM, Crary JL, McGoon MD, et al. Valvular
heart disease associated with fenfluramine-
phentermine. N Engl J Med 1997; 337: 581-8.
27. Kernan WN, Viscoli CM, Brass LM, et al.
Phenylpropanolamine and the risk of hemorrhagic
stroke. N Engl J Med 2000; 343: 1826-32.
28. Lee HK, Choi EB, Park CS. The current status and
future perspectives of studies of cannabinoid receptor
1 antagonists as anti-obesity agents. Curr Top Med
Chem 2009; 9: 482-503.
29. James WPT, Astrup A, Finer N, et al. Effect of
sibutramine on weight maintenance after weight loss:
a randomised trial. Lancet 2000; 356 (Suppl.): 2119-
25.
30. Bickerdike MJ. 5-HT2C receptor agonists as potential
drugs for the treatment of obesity. Curr Top Med
Chem 2003; 3: 885-97.
31. Smith SR, Prosser WA, Donahue DJ, Morgan ME,
Anderson CM, Shanahan WR. Lorcaserin (APD356),
a selective 5-HT 2C agonist, reduces body weight in
obese men and women. Obesity 2009; 17: 494-503.
32. Smith SR, Weissman NJ, Anderson CM, et al.
Multicenter, placebo-controlled trial of lorcaserin for
weight management. N Engl J Med 2010; 363: 245-
56.
33. Vivus Inc. [Accessed June 28, 2013]; Qsymia
(phentermine and topiramate extended-release)
capsules, for oral use. 4/16/2013;
http://www.accessdata.fda.gov/drugsatfda_docs/label/
2013/022580s004lbl.pdf.
34. Tran PT, Thomas A. Summary Minutes of the
Endocrinologic and Metabolic Drugs Advisory
Committee Meeting March 28–29, 2012. Disponible
en
@Real Academia Nacional de Farmacia. Spain